Pharmaceuticals
SK bioscience Board Approves Financing Plan Supported by Korea Growth Fund
* SK bioscience's board approval follows the Financial Services Commission's May 28 announcement selecting the company as a beneficiary of the KRW 300 billion (approximately USD 230 million) Korea Growth Fund financing program * SK bioscience became the first Korean novel drug and vaccine deve...
2026-05-29 20:00
2965
Innovent Biologics and Pfizer Enter Global Strategic Collaboration to Accelerate Development of Innovative Oncology Medicines
SAN FRANCISCO and NEW YORK, and SUZHOU, China, May 28, 2026 /PRNewswire/ -- Innovent Biologics, Inc. (01801.HK) and Pfizer Inc. (NYSE: PFE), today announced the companies have entered into a strategic global licensing and collaboration agreement for the research and development of 12 promising ne...
2026-05-29 07:00
4035
Sino Biological's Cell-Free Protein Synthesis Supports Tencent AI for Life Sciences Lab's Protein Design Study Published in Nature Communications
HOUSTON, May 28, 2026 /PRNewswire/ -- Sino Biological, Inc. (Shenzhen Stock
Exchange: 301047.SZ) has announced that its gene synthesis and cell-free
protein expression workflow was used ina recent study by Tencent AI for Life
Sciences Lab
2026-05-28 23:45
3697
China-US Dual Filing Success: Porton Advanced's End-to-End Bacterial Vector CDMO Solution Accelerates NMPA Approval of Salvectors' Innovative Oncolytic Bacteria Therapy
CRANBURY, N.J. and SUZHOU, China, May 28, 2026 /PRNewswire/ -- Porton Advanced, a leading cell and gene therapy CDMO, recently announced its client Salvectors has received Investigational New Drug (IND) clearance for their proprietary and innovative oncolytic bacteria therapy, "YB1-X7 Injection,"...
2026-05-28 21:00
3194
POMDOCTOR LIMITED Announces Plan to Implement ADS Ratio Change
GUANGZHOU, China, May 28, 2026 /PRNewswire/ -- POMDOCTOR LIMITED (the "Company") (NASDAQ: POM), a leading online medical services platform for chronic diseases in China, today announced that it plans to change the ratio of its American Depositary Shares ("ADSs") to its Class A ordinary shares (th...
2026-05-28 20:00
5254
Aphranel® MagiCCrystal CaHA Filler Achieves EU MDR Certification as a Premium Regenerative Injectable
SHANGHAI, May 28, 2026 /PRNewswire/ -- Moyom Biotechnology announced that its premium regenerative aesthetics product, Aphranel® MagiCCrystal CaHA Filler officially achieved European Union Medical Device Regulation (EU MDR) certification on May 18, 2026, under the registered name "Calcium Hydrox...
2026-05-28 15:55
2670
Leads Biolabs' PD-L1/4-1BB Bispecific Antibody Selected for Oral Presentation at WCLC 2026, Demonstrating Sustained Breakthrough Efficacy Signals in NSCLC
NANJING, China, May 28, 2026 /PRNewswire/ -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) today announced that the Phase II clinical study of its proprietary PD-L1/4-1BB bispecific antibody, Opamtistomig (LBL-024), in combination with chemotherapy for th...
2026-05-28 14:06
3370
HEALEY ALS Platform Trial Regimen I expands to 240 participants
Highlights: * Neurizon announces an expansion to the size of Regimen I intended to support a larger and more informative dataset, with accelerated time to topline readout and no change in funding requirements * Increase in sample size driven by enrolment rate exceeding original expectations ...
2026-05-27 22:41
4433
From Hit Identification to Lead Optimization: Building Scientific Continuity in Early Drug Discovery
SHANGHAI, May 27, 2026 /PRNewswire/ -- On May 20, 2026, Viva Biotech hosted a V-Experts in Conversation webinar, "Managing Complexity in Modern Drug Discovery: A Practical Approach to Integrated Screening & Chemistry." Moderated by Victoria Ouroutzoglou, Associate Director of Business Development...
2026-05-27 20:00
2744
Dizal's ZEGFROVY® (Sunvozertinib) New Drug Application Accepted and Granted Priority Review by China National Medical Products Administration for First-Line Treatment of EGFR Exon 20 Insertion-Mutated Non-Small Cell Lung Cancer
SHANGHAI, May 27, 2026 /PRNewswire/ -- Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of oncology and hematological diseases, announced that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) h...
2026-05-27 18:40
3321
WuXi Biologics Achieves GMP Release of 18th Drug Product Facility, Advancing Integrated Drug Substance to Drug Product Capabilities
SHANGHAI, May 27, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that its Drug Product Facility 15 (DP15), located at the company's Fengxian site in Shanghai, achieved GMP release in April. The facil...
2026-05-27 17:14
4676
Neurophet Launches Joint Study with VHIR on 'Neurophet AQUA MS', Accelerating AI Algorithm Validation
* Collaborative research on AI-based diagnosis of multiple sclerosis, Building a clinical trial dataset * Leveraging large-scale, multi-center brain MRI datasets to detect key lesion biomarkers SEOUL, South Korea, May 26, 2026 /PRNewswire/ -- Neurophet (Co-CEOs Jake Junkil Been and Donghyeon ...
2026-05-26 21:00
5152
Deepening Focus on Autoimmune Diseases, Empowering AI-Driven Drug Discovery
HkeyBio Builds a High-Efficiency Wet-Lab Validation Engine with Comprehensive CRO Service Upgrades in 2026 BOSTON and SUZHOU, China, May 26, 2026 /PRNewswire/ -- I. Industry Background: AI-Driven Drug Discovery Fuels Explosive Demand for Wet-Lab Validation, Creating New Opportunities for Specia...
2026-05-26 20:30
3162
SK bioscience Signs Vaccine Technology Transfer Agreement with Colombia's VECOL to Advance Local Vaccine Manufacturing in Latin America
* SK bioscience collaborates with Colombia's government-led US$260 million vaccine localization initiative through technology transfer and local manufacturing cooperation with state-owned pharmaceutical company VECOL * This alliance enables SK bioscience to enter Latin America by manufacturing...
2026-05-26 20:00
3776
Meet Clicklinks: The Innovation Hub for Original Drug Discovery
SHANGHAI, May 23, 2026 /PRNewswire/ -- For many participants in the innovative drug discovery arena, AI-STAL and SAI-DA are already familiar names within the Sanyou Bio ecosystem. AI-STAL is recognized as the "Grand Master Librarian" safeguarding a Super Trillion Antibody Library, while SAI-DA is...
2026-05-23 22:00
3915
Mabwell Announces Latest Clinical Data on 9MW2821 to Be Presented at 2026 ASCO Annual Meeting as Oral and Poster Presentations
SHANGHAI, May 21, 2026 /PRNewswire/ -- Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, will present multiple clinical study results of its novel Nectin-4-targeting ADC 9MW2821 (Bulumtatug Fuvedotin, BFv) at the 2026 American S...
2026-05-22 11:30
4867
Formosa Pharmaceuticals Announces Presentation of TSY-310 at the 2026 ASCO Annual Meeting
TAIPEI, May 21, 2026 /PRNewswire/ -- Formosa Pharmaceuticals, Inc. announces that its abstract highlighting the differentiated binding profile and preclinical efficacy ofTSY-310, a novel bispecific antibody-drug conjugate (ADC), has been selected for presentation at the American Society of Clinic...
2026-05-22 05:34
3981
Guangzhou Lupeng/Newave Pharmaceutical Inc. Enrolled the First Patient in the Global Phase 3 ROCKET-CLL Trial Evaluating Rocbrutinib (LP-168) vs. Pirtobrutinib in R/R CLL/SLL
Head-to-Head Study Highlights Rocbrutinib as the World's First Fourth-Generation Dual Covalent and Non-Covalent BTK Inhibitor Designed to Overcome Resistance Mutations GUANGZHOU, China and SAN FRANCISCO, May 21, 2026 /PRNewswire/ -- Lupeng Pharmaceutical Ltd, a global clinical-stage biopharmaceu...
2026-05-21 22:00
5324
Hyundai Bioscience Discloses XAFTY®'s IC50 Data for Ebola--"Secured Scientific Evidence for Immediate Treatment"
* Ebola IC50 (0.125μM)—Strong inhibition at less than half the concentration of the clinically-tested COVID-19 (0.28μM). * Clinical safety confirmed through COVID-19 and Dengue clinical trials. * Class-wide efficacy proven by accumulated research data for Hantavirus treatment. * Davey Smit...
2026-05-21 08:38
4086
DeepQure Announces Robust 3-Month Results from HERO-HTN Clinical Study at EuroPCR 2026
PARIS, May 20, 2026 /PRNewswire/ -- DeepQure, a clinical-stage medical device company, today announced robust 3-month clinical data from its HERO-HTN-FIH study during a featured presentation at EuroPCR 2026. The interim results demonstrate that the HyperQure™ extravascular renal denervation (RDN)...
2026-05-20 22:00
4379
Week's Top Stories
Most Reposted
DayOne Appoints Nicolas Aguzin to Board of Directors, Strengthening Global Governance and Capital Markets Expertise
[Picked up by 281 media titles]
2026-05-29 15:50Pudu Robotics and Shenzhen CTID Co. Ltd Launch the World's First Full-Scenario Robot-Serviced Hotel Project
[Picked up by 275 media titles]
2026-06-01 18:00Creality 3D Successfully Listed in Hong Kong
[Picked up by 271 media titles]
2026-05-29 11:21
Creality Charts Next Decade as AI-Powered Consumer 3D Creative Platform, Hong Kong listing anchors the company's full-stack ecosystem shift
[Picked up by 269 media titles]
2026-05-30 11:58
PHOTO & IMAGE SHANGHAI 2026 to Showcase AI Imaging, Content-Creation Technologies and Emerging Visual Trends This July
[Picked up by 269 media titles]
2026-05-29 17:36
Most Read
Creality Charts Next Decade as AI-Powered Consumer 3D Creative Platform, Hong Kong listing anchors the company's full-stack ecosystem shift
2026-05-30 11:58
7838
AMTD's Successful Completion of Acquisition of The Ritz-Carlton, Perth, Valued at A$280 Million
2026-05-29 21:50
7331
Creality 3D Successfully Listed in Hong Kong
2026-05-29 11:21
6667
Zhongchao Inc. Announces Pricing of $5 Million Best Efforts Public Offering
2026-05-29 22:00
6421